The rat prostate tumour cell line R3327 AT-1 was transfected with a gene coding for a fusion protein comprised of cytosine deaminase (CD from E. coli) and thymidine kinase (TK from Herpes simplex virus, HSV-1). The resulting AT-1/CDglyTK cell line was sensitive to the prodrug 5-fluorocytosine (IC
Introduction
Many types of cancer are or become resistant to many of the chemotherapeutic and radiotherapeutic treatments in current use. One strategy for overcoming this situation involves the transfection of tumour cells with a so-called 'suicide' gene. Such a gene may code, for example, for an enzyme capable of converting a relatively non-toxic prodrug into a cytotoxic compound which in turn kills the cells expressing the gene. 1, 2 Cytosine deaminase (CD) is found in some bacteria and fungi, but is absent in mammalian cells. CD deaminates cytosine to uracil and is able to deaminate the relatively non-toxic pyrimidine derivative 5-fluorocytosine (5-FC, 5-FCyt, flucytosine) to the highly potent chemotherapeutic agent 5-fluorouracil (5-FU, 5-FUra), 3 used in the treatment of many cancers. 4, 5 Therefore, the CD gene is a potential suicide gene for tumour therapy, 6 either in the form of bacterial cytosine deaminase (bCD) from Escherichia coli [7] [8] [9] [10] [11] [12] [13] or the more recently proposed yeast CD (yCD) from Saccharomyces cerevisiae. 14, 15 Actually, 5-FU itself is also a prodrug which must be converted intracellularly to cytostatic/cytotoxic fluoronucleotides, such as FUTP and FdUMP. 16 This anabolic activation occurs readily in tumour cells, but also in rapidly proliferating normal cells, resulting in the familiar toxic side-effects of conventional 5-FU therapy. Tumour-selective amplification of the intracellular anabolic activation of 5-FU to FUMP can be achieved by transfection with the E. coli gene for uracil phosphoribosyltransferase (UPRT). [17] [18] [19] Thus, CD-expressing tumour cells can be killed by treatment with 5-FC, whereas normal cells not expressing the CD gene are relatively insensitive to 5-FC at the doses required and are not exposed to toxic levels of 5-FU. An attractive feature of this system is that 5-FC and 5-FU are well established as clinical antifungal and chemotherapeutic drugs, respectively, so that extensive pharmacological information is available on both compounds. The efficiency of this type of gene therapy is thus expected to depend on the tumour-selective efficiency of gene transfection and expression and on the intracellular uptake and conversion of the prodrug (5-FC) to cytotoxic metabolites.
A well-studied alternative gene therapy involves the transfection of tumour cells with the Herpes simplex virus gene for thymidine kinase (TK), which converts the nontoxic drug ganciclovir (GCV) to GCV-monophosphate, which is further metabolized to GCV-triphosphate, a GTP analogue which results in DNA defects and inhibition of DNA synthesis. 1, 8, [20] [21] [22] [23] [24] The CD and TK methods of gene therapy can be combined either by a double transfection or by the use of a gene coding for a fusion protein CDglyTK (CD connected to TK by a polyglycine spacer), as shown by Rogulski et al. 25, 26 One of the key aspects of suicide gene/prodrug strategies is the reliance on the so-called bystander effect, 27 which can compensate for the inability to achieve transfection and expression of the suicide gene in 100% of the tumour cells in vivo; without this effect, nonexpressing cells will survive drug therapy and cause tumour regrowth. There are various possible mechanisms for the bystander effect. For example, toxic metabolites generated in an 'expressing' cell can be transferred to a 'nonexpressing' cell via apoptotic vesicles 27 or via gap junction intercellular communication (GJIC). This latter mechanism is of key importance when the toxic metabolites are charged, phosphorylated species such as the GCV phosphates. These nucleotide analogues cannot leave the cell by free diffusion, and it has been shown that the bystander effect is only active in TK/GCV therapy when gap junctions are available for intermolecular transfer. [21] [22] [23] [24] [28] [29] [30] [31] For CD/5-FC gene therapy there are two possible routes for the bystander effect: (1) an extracellular route involving active or diffusional export of the 5-FU generated by CD and uptake of 5-FU into neighbouring cells 8, 11, 14, 15, [32] [33] [34] or (2) intercellular communication via gap junctions and the transfer of cytotoxic fluoronucleotides (FdUMP, FUTP), as is required for UPRT/5-FU therapy. 18, 19 The possibility of two independent mechanisms for the bystander effect in CD/5-FC therapy suggests that this therapy may be generally superior to TK/GCV therapy, 20, 24 especially when gap junctions are in low abundance or absent. 8, [32] [33] [34] In this study we examined the role of the bystander effect individually for CD/5-FC and TK/GCV therapies in both in vitro and in vivo model systems derived from the Dunning rat prostate adenocarcinoma cell line, R3327 AT-1, which was transfected with a double suicide gene for the fusion protein CDglyTK (bacterial CD from E. coli, TK from HSV-1), following the scheme of Rogulski et al. 25, 26 To date, relatively few publications have appeared concerning gene therapy of prostate carcinoma. 12, 13 The available results indicate a wide range of sensitivities to CD/5-FC gene therapy, and in the case of the human cell line PC-3 only a very weak expression of connexin-43 was detected, 22 suggesting a low abundance of gap junctions. In our model system connexin expression was also low, and TK/GCV therapy showed no bystander effect. Surprisingly, CD/5-FC therapy also showed no bystander effect, suggesting that both gap junction communication and export/diffusion of 5-FU were insufficient. This hypothesis was confirmed by 19 F nuclear magnetic resonance (NMR) spectroscopy of cultured AT-1/CDglyTK cell suspensions in vitro. With this technique it was possible to detect the uptake of 5-FC, its intracellular conversion to 5-FU, a relatively rapid metabolism of 5-FU to fluoronucleotides, but a relatively slow export of 5-FU to the medium. In the past 19 F-NMR has been used extensively to monitor the pharmacokinetics and metabGene Therapy olism of 5-FU in cells, animals and patients, [35] [36] [37] [38] [39] [40] to study the metabolism of 5-FC in yeasts and bacteria, 41 and more recently to evaluate other models of CD gene therapy.
14,42

Results
Growth characteristics of parent AT-1 and transfected cell lines
The experiments described in this report were performed using three rat prostate tumour cell lines (see Materials and methods). The parent AT-1 cell line (Dunning R3327 AT-1 rat prostate adenocarcinoma), the transfected cell line AT-1/CDglyTK containing a double suicide gene coding for the fusion protein cytosine deaminase (E. coli) plus thymidine kinase (Herpes simplex virus type 1), and a control transfected cell line AT-1/GFP containing the gene for green fluorescent protein. The CDglyTK gene was employed for studies of CD/5-FC and TK/GCV therapies alone and in combination with a single cell line. This report will concentrate primarily on the results of 5-FC monotherapy. Table 1 shows that the doubling times in standard culture for AT-1, AT-1/GFP, and AT-1/CDglyTK were 13.1, 14.4 and 14.2 h, respectively. For subcutaneous tumours in vivo in Copenhagen rats, the doubling times were 62.6, 64.6 and 65.8 h, respectively. Thus, transfection results in a minor increase in doubling time, so that the AT-1/GFP cell line is more appropriate as a control in growth studies and for experiments concerning the bystander effect (mixtures of transfected and nontransfected cells, see below).
The sensitivities of the three cell lines to 5-FC and 5-FU were examined under standard culture conditions as shown in Figure 1 . All three lines were sensitive to 5-FU with IC 50 values (drug concentration for a 50% reduction in the number of viable cells) of approximately 3 M (96-h incubation). The AT-1 and AT-1/GFP lines, which do not express cytosine deaminase, were sensitive to 5-FC only at doses above 1 mM (IC 50 = 3 mM), while the CDglyTK + cell line responded with an IC 50 of 78 M. For comparison, the IC 50 value for GCV treatment of CDglyTK + cells is 1.0 M for a 96-h incubation (see Table 1 ).
A further comparison between the parent AT-1 cell line and the CDglyTK + line is shown in Figure 2 . In this experiment cells were cultured for 24 h, incubated for 24 h with various concentrations of 5-FU, and then cultured further with fresh medium. Both cell lines showed essentially the same behaviour. At 5-FU concentrations of 3.8 and 5.8 M, about 50% growth inhibition was observed for 24-48 h after drug removal, but cell counts approached control levels after a further 24 h. With 7.7 or 15 M 5-FU, both cell lines showed growth inhibition of 70-80% at 24 h after treatment, but even at the highest dose a slow growth recovery was observed 3 days after treatment. Thus, incorporation of the CDglyTK suicide gene did not alter the sensitivity of AT-1 cells to 5-FU. However, the results of Figures 1b and 2 indicate that 5-FU concentrations above 10 M and exposure times of greater than 24 h will be necessary for effective cell kill.
Investigation of the bystander effect in culture
The possible operation of a bystander effect for 5-FC treatment can be tested by studying mixed populations Figure 3 ; this line represents the expected behaviour when no bystander effect is operating (maximum cell kill = % CDgkyTK + ). Figure 3 and an absence of a bystander effect were observed for GCV treatment (data not shown). At concentrations of 0.2 and 0.4 M (ϽIC 50 ), there was only minor growth inhibition for 100% transfected cells. At 2.0 M GCV (>IC 50 ) there was progressive growth inhibition following a convex curve similar to that shown for the highest 5-FC concentration in Figure 3 .
Results analogous to
Detection of connexins in AT-1 tumours
A preliminary determination of connexin expression in subcutaneous AT-1 tumours and in other rat tissues was performed using Western blot and immunohistochemical techniques (see Materials and methods). Connexin-43, which has been implicated as a component of gap junctions, was found at high levels in the brain, very low levels in liver, and was not detectable in kidney or heart. Connexin-43 was detected at very low levels (similar to liver) in AT-1 and AT-1/GFP tumours, at somewhat higher levels in 100% AT-1/CDglyTK tumours, but was only barely detectable in mixed tumours containing 20% CDglyTK + cells.
Analysis of 5-FC metabolism using 19 F-NMR spectroscopy
19
F-NMR spectroscopy was employed as an analytical technique for the detection and quantitation of fluorinecontaining compounds. As described in the Materials and methods section, cultured cells were harvested, washed and examined as an intact suspension to determine the concentrations of intracellular metabolites, while the culture medium was measured separately to determine the extracellular concentrations of fluorinated species. Since the NMR measurements required one to several hours of data acquisition to detect micromolar concentrations, all sample handling and measurements were performed at 4°C to stabilize cells and minimize the breakdown of nucleotides.
Large-scale cultures AT-1/CDglyTK cells were prepared under standard conditions to obtain the required number of cells (30-100 × 10 6 ). The cultures were then incubated with high doses of 5-FC for various times Gene Therapy (Table 2 ) and thereafter immediately harvested for NMR examination. The incubation medium was also examined by NMR in a separate measurement. Figure 4 presents the interesting regions of spectra obtained for one of the experiments in Table 2 Table 2 summarises the results of these experiments in terms of metabolite concentrations. The NMR data (signal integrals) from cell suspensions were used to calculate absolute metabolite quantities (in nmol F) which were converted to fmol/cell based on the cell count and finally to an effective M concentration, assuming an average intracellular volume of approximately 1.44 pl (see Materials and methods and footnote to Table 2 ). The results indicate that uptake of 5-FC is not a rapid equilibrium process, but occurs progressively over several hours of incubation, with the intracellular concentration remaining below medium concentration even after 16 h. The conversion of 5-FC to 5-FU via cytosine deaminase is also relatively slow. At 387 M 5-FC no 5-FU was detected after 4 h, while after 16 h about 7% of the total intracellular fluorine-containing metabolites was present as 5-FU and 42% as fluoronucleotides. At 774 M 5-FC conversion to 5-FU and fluoronucleotides was detected after 4 h, but the levels present after 16 h were similar to those obtained with half the 5-FC dose. Of particular importance is the fact that 5-FU was not readily exported from the AT-1/CDglyTK cells. Only after 16-h incubations was 5-FU detectable in the medium and only at levels Ͻ10 M (eg 4.8 M 5-FU after 16 h with 387 M 5-FC).
Treatment of solid tumours in vivo
The transfected cell lines AT-1/GFP and AT-1/CDglyTK were used to establish subcutaneous solid tumours in Copenhagen rats as syngeneic in vivo models for gene therapy (see Materials and methods). In the standard therapy protocol either 5-FC (500 mg = 3.87 mmol per kg body wt) or GCV (30 mg = 0.12 mmol per kg body wt) was administered i.p. once daily for a 14-day cycle. For each animal therapy began when the tumour had grown to a volume of at least 0.3 cm 3 . Figure 5 demonstrates that AT-1/GFP tumours were insensitive to 5-FC at the dose used. The data (not shown, n = 8) for control animals receiving a sham treatment of saline alone were nearly identical to the results with 5-FC treatment. Animals receiving no treatment at all (n = 9, data not shown) or GCV treatment (n = 10, data not shown) exhibited a slightly greater tumour growth (median volume increased by 0.3 cm 3 at day 11). On the other hand, all animals bearing CDglyTK + tumours showed substantial regression following 5-FC treatment (n = 7, Figure 5 ) or GCV treatment (n = 6, data not shown). The median tumour volume decreased to approximately 0.02 cm 3 at the end of 5-FC treatment; tumours were not palpable after GCV treatment. However, complete tumour remission was not achieved (see below); some animals showed slow tumour regrowth following the therapy period.
As models for the bystander effect, mixed tumours were created by inoculating animals with a 20:80 mixture of AT-1/CDglyTK and AT-1/GFP cells. These tumours showed only a retarded growth rate (no regression) during therapy with either 5-FC or GCV, and the median volume was about 60% of that observed for 100% AT-1/GFP control tumours at day 14 ( Figure 5 ). Mixed tumours treated with saline alone (data not shown, n = 8) exhibited the same growth behaviour as shown for 100% AT-1/GFP tumours. As shown in Figure 6 , animals subjected to 5-FC therapy exhibited significant weight loss (5-10%) during the treatment period at the relatively high dose used. The lost weight was regained over the same time period when treatment was terminated. This effect was observed for animals bearing CDglyTK + tumours, as well as for those bearing tumours not expressing cytosine deaminase. Thus, weight loss appears to be a systemic effect of the 5-FC treatment. Interestingly, control animals receiving a sham treatment of saline solution alone (Figure 6 ), exhibited a small reduction in weight or reduced weight gain during the treatment period. Weight loss during GCV treatment was about half the amounts observed for 5-FC treatment.
Survival statistics for tumour-bearing animals were recorded in the form of Kaplan-Meier plots as shown in responded well to 5-FC therapy ( Figure 7 ) and four of seven animals survived tumour-free for 180 days. Following GCV treatment five of six animals were tumour-free, and following combined 5-FC + GCV therapy all seven animals were tumour-free (data not shown). The effect of sham treatment is also clearly evident; the median (50%) survival time was increased from 8.5 days (no treatment) to 18.5 days (saline treatment). For AT-1/GFP tumours (CDglyTK -) the median survival time was 10 days for untreated controls and 12 days for sham or 5-FC treated animals (data not shown).
Finally, the data for the mixed tumours with initially 20% CDglyTK + cells (Figure 8) show that the median survival time increased only slightly from 11 days (no treatment) to 13.5 days (saline treatment), 14 days (5-FC Gene Therapy 
Discussion
Following the strategy of Rogulski et al 25, 26 transfection and expression of the double suicide gene for the fusion protein CDglyTK has been achieved in the Dunning 3327 rat prostate tumour cell line AT-1. Since the AT-1/CDglyTK cell line exhibited a slightly longer doubling time, a second transfected line, AT-1/GFP, containing the gene for green fluorescent protein, was created to serve as a more appropriate CDglyTK -control (see Table 1 ). All three cell lines showed the same sensitivity to 5-FU (IC 50 = approximately 3 M, Figures 1b and 2) , while only the CDglyTK + cell line was sensitive to 5-FC (IC 50 = 78 M) and GCV (IC 50 = 1.0 M). Rogulski et al 25 determined that in the 9L rat glioblastoma cell line the enzyme activity of the CD component of the fusion protein was reduced to about 37% of the level observed following transfection of CD alone, while the TK activity of the fusion protein was enhanced by about a factor of 2.5 compared with TK alone. The 9L/CDglyTK cell line exhibited sensitivities to 5-FC (IC 50 = 77.5 M) and GCV (IC 50 = 0.33 M) that were comparable to our results. Thus, the AT-1/CDglyTK cell line should be a good model for gene therapy of prostate carcinoma, offering dual functionality for 5-FC or GCV treatment or a combination of both. In fact, solid tumours generated in vivo from 100% AT-1/CDglyTK cells responded well to both 5-FC therapy (four of seven animals in remission) and GCV therapy (five of six animals in remission) at nontoxic doses ( Figures 5 and 7) .
However, a further important requirement for a practical suicide gene/prodrug therapy in vivo is the operation of an efficient bystander effect. The expected small percentage of transfected and expressing tumour cells achievable in vivo must be able to produce, by some appropriate mechanism, sufficiently high local concentrations of cytotoxic metabolites in the nontransfected cells which are normally insensitive to the prodrug itself. For TK/GCV therapy the cytotoxic metabolite is GCV-tri-phosphate which normally cannot leave the cell and reach bystander cells by diffusion. However, it has been shown for GCV-sensitive tumours that radiolabeled GCV and phosphorylated species can be detected in both transfected and nontransfected cells. 31 A number of studies have shown rather conclusively that for a variety of tumour types and cell lines an efficient GCV bystander effect requires gap junction intercellular communication (GJIC) 28 and is correlated with high expression of the protein connexin-43 [21] [22] [23] 29 and with efficient intercellular transfer of calcein dye. 23 The GCV bystander effect is modulated by agents which modulate GJIC 23 and is absent for cell lines known to lack gap junctions (electron microscopy: WiDr human colon carcinoma, 8 human renal cell carcinoma 24 ) and for a variety of cell lines shown to express only low levels of connexin-43 (compared with high expression in brain, for example). 21, 22 Furthermore, in a number of cases where GJIC may be weak or lacking, CD/5-FC therapy has proven to be superior to TK/GCV therapy. 8, 20, 24 In general, the expression of connexin-43 and the prevalence of gap junctions appears to vary strongly with cell line, 23 and it may be unwise to rely on GJIC for successful gene therapy unless the therapy includes transfection with a connexin-43 gene. 21 Since CD/5-FC therapy requires the intracellular conversion of 5-FC to 5-FU and its further activation to fluoronucleotides, GJIC can mediate a bystander effect by transport of fluoronucleotides to CD -cells. In fact, this effect is utilized by an alternative strategy, UPRT/5-FU gene therapy, which sensitizes cells to 5-FU by enhancing the direct conversion of 5-FU to FUMP, leading to enhanced levels of FUTP and FdUMP. 18 The fluoronucleotides are transported to nontransfected cells by GJIC. [17] [18] [19] However, CD/5-FC therapy offers a second, extracellular route for the bystander effect, namely, the export of 5-FU (assumed to be freely diffusable as a small, uncharged molecule) and uptake by neighboring cells. This mechanism does not require cell-cell contact, can be detected in low-density cell cultures, and can operate even in a systemic manner in vivo. The extracellular route via 5-FU has been implicated in most of the CD/5-FC studies where the bystander effect has been examined, especially when the GJIC mechanism can be ruled out. 8, [11] [12] [13] [14] [15] 24, [32] [33] [34] Unfortunately, we have found to date little data on gene therapy of prostate carcinoma and its relationship to GJIC. The human cell line PC-3 was shown to have low expression of connexin-43, but gene therapy was not investigated. 22 A recent CD/5-FC therapy study of three prostate carcinoma lines showed a large variation in the strength of the bystander effect in vitro, presumably via 5-FU and the extracellular diffusional route. In CD + /CD -cocultures 100% killing at 500 M 5-FC (14 days) was achieved with the following populations of CD + cells: 5% LNCaP, 10% RM-1, 50% DU-145. 12 The human prostate carcinoma lines LNCaP, PC-3 and DU-145 were examined by Miller et al, 13 who found that while their sensitivities to 5-FU were quite similar (IC 50 = 1.5, 3.1, 3.8 M, respectively), the sensitivity to 5-FC varied strongly (IC 50 = 8, 39, 155 M). Unfortunately, the bystander effect was not investigated in this study.
For our model system we examined the bystander effect in vitro using cocultures of AT-1/CDglyTK and AT-1/GFP (CDglyTK -) cells. We found no evidence of a bystander effect for either GCV or 5-FC treatment ( Figure   3 ), even at doses well above the IC 50 (Figures 5 and 8) . Thus, our rat prostate tumour model for TK or CD gene therapy fails with respect to the required bystander effect.
The absence of the bystander effect for TK/GCV therapy indicates that GJIC is weak in our system and is consistent with our observation that expression of connexins is low in AT-1 tumour tissue, expecially in tumours derived from a 20:80 mixture of CDglyTK + /CDglyTK -cells. Thus, GJIC will also be unavailable as a mechanism for a bystander effect in 5-FC treatment. Under such conditions in other model systems, CD/5-FC therapy has proved to be superior to TK/GCV therapy. This was not the case in our system, implying that the extracellular route for a bystander effect via 5-FU was also ineffective.
An explanation for the failure of the extracellular bystander effect is provided by the 19 F-NMR spectroscopic data which allowed us to determine the intra-and extracellular concentrations of the key metabolites involved in 5-FU metabolism ( Figure 4 , Table 2 ). Experiments with cultured CDglyTK + cells demonstrated that uptake of 5-FC and conversion to 5-FU proceeded relatively slowly over a period of several hours, but that intracellular anabolic conversion of 5-FU to cytotoxic fluoronucleotides was quite efficient (approximately 80% after 16 h), while conversion to relatively nontoxic catabolites was not detected.
In most normal tissues and especially in the liver, detoxification of 5-FU proceeds via dihydropyrimidine dehydrogenase (DPD) 4, 6 to give DHFU, which is converted to FUPA and FBAL via subsequent reactions. These catabolites can be readily detected in the plasma and urine of patients or animals undergoing fluoropyrimidine therapy. 35, 36 The enzyme DPD may be expressed in some tumour cell lines, 43 and its activity has been related to the 5-FU sensitivity of such cell lines. 44 However, our results and many other F-NMR data in Table 2 indicate that this requirement was not met in culture. In fact, a significant 5-FU concentration gradient existed between the intra-and extracellular regions with 5-FU remaining preferentially inside the tumour cells. Such a 'trapping' of 5-FU within tumour cells and tissues has been noted in a number of previous studies of 5-FU therapy [45] [46] [47] [48] and has been rationalized on the basis of a negative intra-to extracellular pH gradient now known to be common in tumour tissue (⌬pH = pH e -pH i = approximately -0.4). [48] [49] [50] Since the solubility of 5-FU increases with increasing pH (pK a = approximately 7.7 for the equilibrium between neutral and negatively charged species 39 ), a higher pH within tumour cells compared with the interstitium can result in intracellular trapping. 51 (Table 2 ). Thus, in culture a major fraction of the total 5-FU produced can in fact be exported, even when a negative concentration gradient exists at equilibrium. However, the extracellular 5-FU concentration will remain low due to the combined effects of a relatively large medium volume and a limiting concentration gradient, resulting in a weak bystander effect in culture. In the in vivo model the ratio of extra-to intracellular volume within tumour tissue will be much more favourable (aproximately 1:1) so that much higher local concentrations of 5-FU in the interstitium might be expected (> IC 50 ), compared with that achieved in culture medium, but only if 5-FU is rapidly and freely diffusible. If the rate of export is too slow to achieve equilibrium, or if a negative concentration gradient is maintained even at equilibrium, then the achievable concentration of 5-FU in the interstitium and the bystander effect will be limited. Furthermore, tissue clearance of 5-FU via the vasculature and efficient catabolism of 5-FU in the liver will also serve to limit the extracellular concentration of drug in the in vivo model.
Thus, intracellular trapping of 5-FU is the most likely reason for failure of the 'extracellular' bystander effect for 5-FC treatment with our tumour model. The hypothesis that 5-FU will always behave as a freely diffusible and permeable metabolite, 8, 15, 34 as required for an optimal bystander effect, is too simplistic. Furthermore, efficient conversion of 5-FU to cytotoxic fluoronucleotides will (1) limit the amount of 5-FU available for export; and (2) may shut down the 5-FU 'factory' by efficiently killing CD + cells before a significant bystander effect can occur. For example, Lawrence et al 34 have shown with a rat hepatocyte model that CD -bystander killing actually decreased while CD + killing increased as 5-FC concentration was increased. Thus, there are a number of possible scenarios where the bystander effect will fail: when the 5-FC dose or uptake is insufficient for rapid 5-FU production; when 5-FU export is limited by slow conversion, rapid anabolism, or a negative ⌬pH; or when high doses of 5-FC result in rapid CD + cell kill before sufficient 5-FU can be released.
It has been shown by other groups that in appropriate model systems CD/5-FC therapy can indeed induce a strong bystander effect not only in vitro but also in vivo. 9, 10 For example, for the human colorectal carcinoma cell line WiDr transfected with the bacterial gene from E. coli (bCD), it was demonstrated that at 500 mg/kg 5-FC dosGene Therapy age only 2-4% bCD + cells (IC 50 = 27 M) were sufficient to achieve a significant bystander effect and tumour regression in a mouse model in vivo. 8, 32 The limited data available for prostate models (see above) indicate that the strongest bystander effect was obtained with the LNCaP/bCD cell line which had the lowest IC 50 for 5-FC (8 M) and for 5-FU (1.5 M). 13 Our AT-1 model exhibited no bystander effect and had a much higher IC 50 for 5-FC, ie intermediate between the values found for PC-3 and DU-145 cell lines, and DU-145 required at least 50% CD + cells to achieve a bystander effect in cocultures. 12 Thus, a lower IC 50 for 5-FC may reflect more efficient conversion to 5-FU, leading to higher intracellular concentrations, more rapid export and higher extracellular concentrations of 5-FU, thus compensating for the 'trapping' effect and leading to an improved bystander effect.
Compared with bCD, the yeast CD from Saccharomyces cerevisiae exhibits a much higher catalytic efficiency (lower K m , higher V max ) for conversion of 5-FC to 5-FU. 14, 15 In an in vivo 19 F-NMR study of an HT29/yCD colorectal carcinoma model system, rapid conversion of 5-FC to 5-FU, rapid elimination of 5-FU, and slow conversion to fluoronucleotides were observed, with serum 5-FU levels reaching approximately 20 M at 90 min after a 1 g/kg 5-FC treatment.
14 Thus, the behaviour of this model system appears to be well suited to the generation of a bystander effect. On the other hand, an analogous HT29/bCD model system failed to exhibit NMR-detectable 5-FU metabolism.
14 It was also shown for a model system involving a murine squamous cell carcinoma 15 that a strongly enhanced 5-FC conversion rate, lower IC 50 (approximately 10 M), and an improved bystander effect were obtained for yCD transfected cells versus bCD transfected cells. Thus, yCD/5-FC therapy may provide a much more favourable relationship for the rates of 5-FU production and export compared with the rate of fluoronucleotide production (cell kill), compensating for a potentially unavoidable intra-to extracellular 5-FU concentration gradient (trapping). The promising results obtained with yCD gene therapy suggest that this approach should be considered for future experiments with model systems such as ours where bCD gene therapy did not result in a satisfactory bystander effect.
A significant side-effect observed in our model system with both CD + and CD -tumours was reversible animal weight loss during extended i.p. 5-FC treatment ( Figure  6 ). Huber et al 7 observed no weight loss or toxicity at 5-FC doses up to 675 mg/kg in nu/nu (CD-1)BR nude mice. However, Stegman et al 14 reported up to 15% weight loss for nu/nu CD-1 nude mice bearing a large tumour load after a 4-day treatment cycle (500 mg/kg). Thus, for animal studies with multiple 5-FC i.p. treatments, a dosage of not more than 500 mg/kg appears warranted.
Materials and methods
Cell lines
The Dunning prostate adenocarcinoma cell line, R3327 AT-1, was originally derived from a spontaneous prostate tumour in a male Copenhagen rat. 52 AT-1 is a slowgrowing, non-metastatic, anaplastic and hormone-insensitive tumour with a histology and biochemical profile similar to those for human prostate carcinoma. The cell line was obtained in 1987 from Dr JT Isaacs (John Hopkins University, Baltimore, MD, USA) and has been maintained in the DKFZ tumour bank. AT-1 and transfected AT-1 cell lines were grown in Roswell Park Memorial Institute medium (RPMI 1640, Sigma, St Louis, MO, USA) supplemented with 10% heat-inactivated fetal calf serum (FCS, Sigma) and 2 mM glutamine (Sigma), pH 7.4. Cells were cultured in 75-cm 2 flasks (Greiner, Frichenhausen, Germany) at 37°C under 5% CO 2 in air at 95% humidity.
Transfected cell lines
The AT-1/CDglyTK cell line was kindly provided by JH Kim (Henry Ford Hospital, Detroit, MI, USA). AT-1 cells were transfected with a bifunctional fusion gene pWZLneoCDglyTK 25, 26 which coded for a fusion protein, comprising cytosine deaminase (CD) from E. coli 53 and thymidine kinase (TK) from HSV-1 linked via a glycine spacer, and which also contained the neomycin resistance gene. CDglyTK + cells were selected by culturing in the presence of 0.5 mg/ml geneticin (G418, Gibco BRL, Grand Island, NY, USA). Expression of the CDglyTK fusion protein was confirmed by binding of a polyclonal anti-cytosine deaminase antibody. 54 The protein-antibody complex was stained with the aid of 3,3'-diaminobenzidine (DAB) (Vector Laboratories, Burlingame, CA, USA) and visualized under the microscope as granula distributed throughout the cytoplasm.
The AT-1/GFP cell line was obtained by transfecting AT-1 with the pEGFP-C3 plasmid (Clontech, Palo Alto, CA, USA), containing the genes for enhanced green fluorescent protein (EGFP) and neomycin resistance. In 24-well plates, 3 × 10 4 AT-1 cells per well were seeded and incubated overnight. For each well a mixture of 3 g pEGFP-C3 DNA and 20 l Lipofectin (Gibco BRL) in 300 l serum-free RPMI 1640 was prepared and equilibrated at room temperature for 15 min. The cells in each well were washed with serum-free RPMI 1640, and the Lipofectin/DNA complex was then added. After incubation for 5 h at 37°C, the medium containing the lipid/DNA complex was replaced with 1 ml of fresh RPMI 1640 supplemented with 10% FCS. Three days later transfected cells were selected by the addition of 0.5 mg/ml geneticin to establish a stable cell line.
Doubling times for the native and transfected cell lines in culture were determined by seeding 4 × 10 4 cells in 25-cm 2 flasks. Cell counts were determined in triplicate at 24, 48, 72 and 96 h. In other experiments cells were incubated for 24 h with 5-FU (0-15 M) and the medium was then replaced with fresh drug-free medium. At this point a selected fraction of the wells corresponding to each drug concentration was assayed for cell viability, and at subsequent 24-h intervals analogous assays were performed to obtain a time course for response to drug treatment.
Cell viability assay for assessing drug sensitivity
The MTS assay itself was performed by adding to each well 20 l of a mixture of the kit reagents prepared from 100 l PMS reagent (phenazine methosulfate) and 2.0 ml MTS reagent. The plates were then incubated for 90 min at 37°C under 5% CO 2 in air with 95% humidity. Finally, the absorbance A 490 was determined for each well using an ELISA reader (BioRad, Hercules, CA, USA).
Cellular protein determination
Total protein was isolated from homogenized cells using TRIzol reagent (Gibco BRL) according to the method of Chomczynski 55 and was determined in triplicate by the colorimetric method of Bradford 56 using Coomassie Blue G250 (Bradford reagent; BioRad). A calibration curve was prepared using bovine serum albumin (Boehringer Mannheim, Mannheim, Germany) in TRIzol. Absorbance at 595 nm was determined with an ELISA reader.
Detection of connexins
Tumour tissue lysates were analysed using Western blot and immunohistochemical methods: SDS-polyacrylamide gel electrophoresis, blotting on a nitrocellulose membrane (Amersham Pharmacia, Foster City, CA, USA), incubation overnight with an appropriate monoclonal antibody (Chemicon, Germany) followed by incubation for 1 h with secondary IgG antibody coupled to horseradish peroxidase. Connexin-43 was detected at MW 43 kDa by peroxidase-catalysed chemiluminescence of luminol as recorded on autoradiography film (Hyperfilm ECL, Amersham Pharmacia). The final cell pellet (0.3-1 × 10 8 cells) was resuspended in a minimum volume (0.3-0.5 ml) of the HEPES/Ringer buffer and placed in an 8-mm diameter NMR sample tube (Wilmad, Buena, NJ, USA). As the cells settled to the bottom of the sample tube, sufficient buffer was layered on top to fill the tube to a height of 30 mm. The 8-mm sample tube was then inserted into a 10-mm NMR tube containing 150 mM NaCl in D 2 O (required for spectrometer stabilisation via deuterium lock). The vertical position of the 8-mm tube was adjusted within the 10-mm tube so that the cell pellet (5-28 mm in height) was always centred within the NMR radio-frequency (rf) receiver coil (24 mm in height) while the bottom of the 10-mm sample tube was positioned via the sample spinner at a constant 20 mm below the rf coil centre. This concentric tube configuration resulted in optimum positioning of the settled cell mass relative to the rf coil, while maintaining a large volume of buffer at a constant position for reproducible rf coil tuning and magnetic field homogeneity. For NMR measurements of the incubation culture medium, the 8-mm sample tube was filled to a constant height of 30 mm.
Preparation of cell samples for 19 F-NMR measurements
F-NMR spectroscopy and metabolite quantification
19 F-NMR spectroscopy of cell suspensions and incubation medium was performed at 470 MHz (11.7 T) and 4°C with a Bruker AM-500 FT-NMR spectrometer using a 10-mm probe head and the sample tube configuration described above, including a 1.5-mm reference capillary containing 1,2-difluorotetrachloroethane (DFTCE) in C 6 D 6 . The resonance frequency (chemical shift) of the DFTCE reference signal was calibrated as +7.766 ppm at 4°C relative to trifluoroacetate (TFA, 0.0 ppm) in 50 mM HEPES, pH 7.
Data acquisition for cell suspensions began approximately 60-90 min after harvest. The following parameters were used: spectral width 25 kHz (region -78 to -132 ppm where the signals for 5-FC, 5-FU and metabolites were expected); rf pulse width 12 s (36°flip angle), repetition time 1.0 s, no 1 H-decoupling. A total of 3600 transients were acquired in 1 h, and for cell suspensions four successive 1-h acquisitions were stored separately. Comparison of successive spectra showed than the 5-FC concentration was stable over 4 h while only a slow, partial conversion of fluoronucleotides back to 5-FU (maximum 25% after 4 h) could be detected in some cases. Therefore, the four acquired spectra were added together to improve the signal-to-noise ratio, resulting in a detection threshold of approximately 2 nmol F. For incubation medium, data acquisition was performed for up to 10 h to achieve a detection threshold of 1 M for 5-FU. The 19 F spin-lattice relaxation time T 1 for 5-FC in medium was measured by inversion recovery techniques and found to be 1.71 ± 0.021 s at 4°C.
Drug and metabolite quantification was performed as follows. The 19 F-NMR spectra were processed using a constant absolute intensity scale and the observed signals were digitally integrated using the Bruker software routines. Under the data acquisition conditions employed Gene Therapy here, the signal integrals can be assumed to be proportional to (1) the molar concentration of fluorine-containing metabolites in large volumes (medium); or (2) the absolute molar quantities of metabolites within the sensitive volume of the rf receiver coil (cell pellet). For measurements of incubation medium the concentrations of fluorine-containing species were simply calculated from their measured signal integrals relative to the 5-FC signal integral and the known concentration of 5-FC in the incubation medium.
For the analysis of cell suspension data, it was necessary to perform a separate calibration experiment to determine the proportionality constant for signal integral versus absolute nmol F, for example. Various volumes of incubation medium (0.2-1.0 ml) with known 5-FC concentration were placed in the 8-mm sample tube and positioned with the rf coil in the manner employed for cell suspension measurements. Spectra were acquired using our standard conditions and N transients. A plot of 5-FC signal integral per 1000 transients (I 1000 = I (1000/N)) versus ml medium or versus the corresponding nmol 5-FC displayed an initial linear behaviour followed by a plateau region when the sample volume exceeded the effective rf coil volume (0.70 ml in an 8-mm tube). From the initial linear slope, the calibration constant of 31.2 nmol F per unit I 1000 was determined. Thus, the I 1000 data obtained from cell suspensions could be converted to absolute nmol quantities for drug or metabolites by simply multiplying I 1000 by 31.2. From the cell counts obtained at harvest, the total number of cells in each NMR sample was known. Thus, the absolute metabolite quantities (nmol) determined by NMR could be expressed in terms of fmol/cell, for example. From FACS measurements typical cell diameters were found to be 12-15 m. Therefore, to estimate the effective intracellular concentrations (for a homogeneous distribution), we assumed an average cell radius r ave = 7 m, which gives an average cell volume of V ave = 1.437 pl. In addition, total cellular protein was determined for the NMR samples (for 10 6 cells, mean: 362.4 g, range: 356-368 g, n = 4). Thus, for the quantitation of intracellular metabolites we have the equivalence 1 fmol/cell = 2.759 nmol/mg protein = 696 M.
Animal studies
In vivo tumour growth studies, with and without 5-FC treatment, were performed using juvenile male Copenhagen rats (180 ± 20 g; Charles River, Sulzbach, Germany). The animals were held under sterile (SPF) conditions as pairs in macrolon cages (size III) at 24 ± 1°C and 50 ± 10% humidity with a 12-h light/dark cycle. Water and rat/mouse chuck (Atromin, Lage, Germany) food pellets were available ad libitum. Permission for the experiments and animal handling were according to German regulations (permit No. .81/138/99, Regierungspräsidium Karlsruhe).
Tumours were inoculated by injecting subcutaneously (s.c.) into a rear thigh 10 6 tumour cells in 300 l RPMI 1640. Experiments were performed with AT-1/CDglyTK cells, AT-1/GFP, or a mixture of 80% AT-1/GFP and 20% AT-1/CDglyTK cells. Tumour size was estimated by measuring two orthogonal diameters with a caliper three times weekly, and tumour volume was calculated as (4/3)r 1 2 r 2 , where r 1 and r 2 are the radii for the shorter and longer axis, respectively. Animal body weight was determined twice weekly.
Treatment began when tumours reached a volume of at least 0.3 cm 3 (typically 8-12 days after inoculation, median: approximately 0.5 cm 3 ). The animals received an injection (i.p.) once a day for 14 days of freshly prepared 5-FC (500 mg = 3.87 mmol per kg body weight as a suspension in 1 ml 0.9% NaCl (Braun, Melsungen, Germany)) or GCV (30 mg = 0.12 mmol per kg body weight). Controls received either no treatment or a sham treatment of 1 ml 0.9% NaCl. Surviving animals were killed by CO 2 inhalation when the tumour reached a volume of 4.0 cm 3 or at 180 days following tumour inoculation.
Doubling times for subcutaneous tumours in vivo were determined from median tumour volume versus time for AT-1 (n = 6), AT-1/GFP (n = 6), and AT-1/CDglyTK (n = 5).
Data analysis and statistics
Tumour cell doubling times were determined by exponential regression analysis. The cell viability data (MTS assay) are presented in the Figures as % of control values (means of four determinations; standard deviation typically 5%). IC 50 values were estimated graphically. The metabolite concentration data determined by NMR represent single determinations with an estimated absolute accuracy of ±15%.
For in vivo studies the median tumour volumes of treated and control rats were compared over time. The statistical significance of differences between groups was estimated as the P value for a two-sided t test, assuming unequal variance (Microsoft EXCEL software). For survival studies (Kaplan-Meier plots) the cumulative survival as % of animals in a given group was plotted versus time. The biological endpoint for nonsurvival was defined as T 5 , where tumour volume reached five times the minimum initial volume (ie T 5 = 1.5 cm 3 for all animals). At this point animals were killed. The significance of differences between treatment groups was determined by a log-rank test (SAS software).
